ASCO 2023: Adding ribociclib to hormonal therapy reduces risk of recurrence for people with most common subtype of breast cancer

3 Jun 2023
ASCO 2023: Adding ribociclib to hormonal therapy reduces risk of recurrence for people with most common subtype of breast cancer

Adding the targeted therapy drug ribociclib to hormonal (endocrine) therapy showed a significant improvement in invasive disease-free survival (iDFS) for people with HR-positive, HER2-negative early-stage breast cancer. The research was presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

HR-positive, HER2-negative breast cancer is the most common subtype of the disease, making up nearly 70% of all breast cancer cases in the United States.

Study participants were randomly assigned to receive either adjuvant ribociclib for 3 years with hormonal therapy for at least 5 years or hormonal therapy alone. At a median follow-up of 34 months, 20.2% of participants in the ribociclib group had completed 3 years of treatment and 56.8% had completed 2 years of treatment. Overall, 74.7% of participants remained on the study treatment at data cutoff, with 1,984 patients on ribociclib and 1,826 patients on hormonal therapy alone.

The study found that adding ribociclib to hormonal therapy led to a significant improvement in iDFS compared with hormonal therapy alone. Researchers evaluated iDFS after 426 iDFS events occurred, a number that was prespecified for the interim analysis. Of those events, 189 occurred in the ribociclib group (7.4% of patients) vs. 237 in the hormonal therapy alone group (9.2% of patients).

The 3-year iDFS rates were 90.4% in the ribociclib group compared with 87.1% in the hormonal therapy alone group. Overall, the addition of ribociclib reduced the risk for recurrence by 25%. The iDFS benefit seen in the ribociclib group was generally consistent across clinically relevant patient subgroups. Ribociclib also showed more favourable outcomes in overall survival, recurrence-free survival, and distant disease-free survival.

For patients receiving ribociclib, the most common adverse effects were neutropenia and joint pain. Rates of gastrointestinal adverse effects and fatigue were low in patients receiving ribociclib. For patients receiving hormonal therapy alone, the most common adverse effects were joint pain and hot flash.

“Currently approved targeted treatments can only be used in a small population of patients diagnosed with HR-positive, HER2-negative early breast cancer, leaving many without an effective treatment option for reducing risk of the cancer returning,” said lead author Dennis J. Slamon, MD, PhD, Director of Clinical/Translational Research and Director of the Revlon/UCLA Women's Cancer Research Program at the UCLA Jonsson Comprehensive Cancer Center in Los Angeles, California. “Thus, there is a significant unmet need for both reducing the risk of recurrence and providing a tolerable treatment option that keeps patients cancer-free without disrupting their daily life. The NATALEE study investigated the addition of ribociclib to standard-of-care adjuvant endocrine therapy and was specifically designed to address these unmet needs.”

“While early, these results are very promising and suggest that there will be a role for adjuvant ribociclib for stage II and higher hormone receptor-positive (HR-positive), HER2-negative breast cancer,” said Rita Nanda, MD, ASCO Expert. 

HR-positive breast cancer makes up about two-thirds of breast cancers and is more common after menopause.2 According to the authors, about one-third of people with stage II HR-positive, HER2-negative disease experience a recurrence following standard-of-care treatment and more than one-half of people with stage III disease experience a recurrence. If a recurrence occurs, it is often at a more advanced stage.

Ribociclib is a type of targeted therapy called a small molecule inhibitor. It works by targeting proteins in breast cancer cells called CDK4 and CDK6, which modulate cell growth, including the growth of cancer cells. Ribociclib is currently approved by the U.S. Food and Drug Administration to treat HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor for premenopausal people or in combination with fulvestrant for postmenopausal people. While ribociclib has previously shown survival benefits in people with metastatic disease, in this study, researchers showed that it may also improve outcomes for people with earlier-stage disease, including those with cancer that has not yet spread to the lymph nodes.

The NATALEE phase III clinical trial included men and premenopausal or postmenopausal women from 20 different countries with stage IIA, IIB, or III HR-positive, HER2-negative breast cancer at risk for recurrence. Participants were randomly assigned to receive either 400 milligrams (mg) of adjuvant ribociclib for 3 years with hormonal therapy for at least 5 years (2,549 patients) or hormonal therapy alone for at least 5 years (2,552 patients). Men and premenopausal women also received goserelin (Zoladex), an ovarian suppression drug. Prior hormonal therapy use was allowed if it was initiated no more than 1 year before the start of the study.

The current recommended starting dose of ribociclib for people with metastatic disease is 600 mg. However, an extended duration of treatment can help to stop cells from duplicating and dividing and destroy any remaining cancer cells. Because of this, study authors chose a 3-year treatment duration of ribociclib at a dose of 400 mg to reduce side effects while maintaining efficacy.

Researchers will continue to evaluate how the addition of ribociclib to hormonal therapy impacts the quality of life and will follow patients to observe long-term outcomes.

The study was funded by Novartis Pharmaceuticals Corporation.

Watch Dr Slamon's interview here.

Source: ASCO